735 reports of this reaction
3.2% of all RASAGILINE MESYLATE reports
#3 most reported adverse reaction
DYSKINESIA is the #3 most commonly reported adverse reaction for RASAGILINE MESYLATE, manufactured by Teva Neuroscience, Inc.. There are 735 FDA adverse event reports linking RASAGILINE MESYLATE to DYSKINESIA. This represents approximately 3.2% of all 23,100 adverse event reports for this drug.
Patients taking RASAGILINE MESYLATE who experience dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSKINESIA is moderately reported among RASAGILINE MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to dyskinesia, the following adverse reactions have been reported for RASAGILINE MESYLATE:
The following drugs have also been linked to dyskinesia in FDA adverse event reports:
DYSKINESIA has been reported as an adverse event in 735 FDA reports for RASAGILINE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSKINESIA accounts for approximately 3.2% of all adverse event reports for RASAGILINE MESYLATE, making it one of the most commonly reported side effect.
If you experience dyskinesia while taking RASAGILINE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.